he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源URL
- 2022-05-10可惜!福建一10个月女婴重度发育迟滞!疫情之后,别忘了孩子的日常体检
- 2022-05-05癫痫癫痫时的前兆
- 2022-04-262013年国际抗癫痫联会抗癫痫药使用指南
- 2022-04-20隐源性哮喘死亡率翻倍
- 2022-04-12FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 2022-04-11银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- 复杂腹腔感染:β内酰胺联合治疗不优于单药
- 成都西南妇科医院:照顾山区儿童,让冬天不再寒冷
- 月经性癫痫患者妊娠期癫痫控制更好
- 女人过早对夫妻不利
- 病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- 灼烧综合征的原因不容忽视治疗
- 凌腾医学宣布,卡妥索双抗对介苗治疗失败的非肌层浸润性膀胱癌的第一次临床试验已经完成
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 心率多少正常 如何保持正常心率不变
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 不注意这些问题,吃多少药都没用!
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- Ann Otol Rhinol Laryngol:腺样体切除术后与顽固性鼻塞有关的因素分析
- 90%的人误解这些妇科常识!
- 癫痫患者春节期间的饮食问题
- 治疗白癜风的方法 牢记这些治疗白癜风更省钱
- Medpage Today:不同类型的抗癫痫药物更有利
- 癫痫症状 如何护理癫痫患者?
- LEEP手术知道多少?
- 癫痫治疗障碍仍难以克服
- 肺源性心脏病可能并发左心功能不全吗?如何制定治疗方案?
- 抗癫痫药物预防新发癫痫:任重而道远
- 常见的癫痫病因有哪些?
- 白癜风患者吃生葵花子有助于治疗吗?
- 脑部寄生虫引起的癫痫该怎么治台
- 研究者告诉你癫痫病的治疗好方法
- 罗氏制药发布致医生信警示甲氟喹的神经精神高血压
- 同道分享的病例:花了三个周内才明确诊断
- 老人癫痫病患者发作的病因主要是有哪些
- 神经胶质瘤扣留的谷氨酸盐可诱发癫痫
- 怎样治疗癫痫病最直接
- 羊癫疯最出色的治疗方法都有哪些
- 小儿抽搐始得怎么治疗是癫痫病吗
- 2015年第31届国际病症大会(IEC)
- 亚甲基四氢叶酸还原酶缺陷导致的家族连续性癫痫连续性脑病
- 癫痫病频仍的病因有哪些
- 【用药问答】治疗癫痫大心脏病和局限性心脏病的药物?